Combined immunoscore and pan-immune inflammation value associated with pathological response and survival outcomes in esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy
The IS + PIV dual-parameter model, by integrating local immune activity and systemic inflammatory status, accurately identifies NACI beneficiaries (high IS + low PIV) and high-risk patients (low IS + high PIV), providing an efficient prognostic tool for personalized treatment strategies.
Authors
- Jingyu Wu
- Sui Chen (ORCID: https://orcid.org/0000-0001-7251-7760)
- Qi-hong Zhong
- H. Zhang
- Fei-long Guo (ORCID: https://orcid.org/0000-0001-5804-5816)
- Zhen-yang Zhang
- Ye-qin Zhang
- Jiangbo Lin (ORCID: https://orcid.org/0000-0002-2405-5490)
- Wen-wei Lin
- Jiang-Shan Huang
Institutions
- Fujian Medical University (CN)
- Union Hospital (CN)
Publication Details
- Journal
- International Journal of Surgery
- Published
- 2025-10-07
- DOI
- https://doi.org/10.1097/js9.0000000000003559
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05